Coding Ahead
CasePilot
Medical Coding Assistant
Case2Code
Search and Code Lookup Tool
CareerCenter
Medical Coding Job Board
Log in Register free account

Need help choosing the right code?

Ask CasePilot about procedures, modifiers, bundling, and coding guidance.

Try CasePilot

Official Description

Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; giardia

© Copyright 2026 American Medical Association. All rights reserved.

Common Language Description

The CPT® Code 87329 refers to a laboratory test specifically designed for the detection of giardia antigen in fecal samples using various immunoassay techniques. Giardia is a protozoan parasite that can contaminate food and water, leading to gastrointestinal issues such as diarrhea, abdominal pain, and weight loss when ingested. The test employs several methodologies, including enzyme immunoassay (EIA), enzyme-linked immunosorbent assay (ELISA), fluorescence immunoassay (FIA), and immunochemiluminometric assay (IMCA), to identify the presence of giardia antigens. These techniques are capable of detecting even minute quantities of the antigen by utilizing specific antibodies that bind to the giardia antigen in the sample. In the laboratory, a fecal sample is collected, which may be preserved in formalin or sent fresh for analysis. The EIA and ELISA methods involve adding a secondary enzyme-labeled antibody that binds to the antigen-antibody complex, resulting in a chromogenic reaction that produces a visible color change or fluorescence, allowing for qualitative or semi-quantitative assessment based on colorimetric readings. The FIA method utilizes a fluorescent compound to detect the binding of the detection antibody to the giardia antigen, emitting light at a different wavelength, which is measured to determine the presence of the antigen. Lastly, the IMCA technique employs antibodies labeled with a chemiluminescent substance, enabling the identification and quantification of the antigen-antibody complex through light emission. This comprehensive approach ensures accurate detection of giardia, aiding in the diagnosis and management of infections caused by this parasite.

© Copyright 2026 Coding Ahead. All rights reserved.

1. Indications

The procedure associated with CPT® Code 87329 is indicated for the detection of giardia antigen in patients who present with gastrointestinal symptoms. The following conditions may warrant the performance of this test:

  • Diarrhea The presence of persistent or acute diarrhea that may suggest a parasitic infection.
  • Gastrointestinal Symptoms Symptoms such as abdominal pain, bloating, and nausea that could be associated with giardiasis.
  • Weight Loss Unexplained weight loss that may be linked to malabsorption due to giardia infection.

2. Procedure

The procedure for detecting giardia antigen using CPT® Code 87329 involves several key steps, which are outlined below:

  • Sample Collection A fecal sample is collected from the patient, which can either be preserved in formalin or sent fresh to the laboratory for analysis. Proper collection and handling of the sample are crucial to ensure accurate test results.
  • Preparation of the Sample The laboratory processes the fecal sample to prepare it for testing. This may involve homogenizing the sample and diluting it as necessary to facilitate the immunoassay techniques.
  • Immunoassay Technique Application The prepared sample undergoes testing using one of the immunoassay techniques, such as EIA, ELISA, FIA, or IMCA. Each method employs specific antibodies that bind to the giardia antigen present in the sample.
  • Detection and Measurement The presence of the giardia antigen is detected through a chromogenic reaction, fluorescence, or light emission, depending on the technique used. The results are assessed qualitatively or semi-quantitatively based on the intensity of the color change or fluorescence observed.
  • Result Interpretation The laboratory interprets the results, determining whether the giardia antigen is present in the sample, which aids in diagnosing giardiasis.

3. Post-Procedure

After the procedure, the laboratory will provide the results to the requesting physician, who will interpret the findings in the context of the patient's clinical presentation. If giardia antigen is detected, appropriate treatment options will be discussed with the patient. It is important for the physician to consider follow-up testing or additional diagnostic procedures if symptoms persist or if there are concerns about the accuracy of the test results. Patients may also be advised on preventive measures to avoid future infections, such as proper hygiene and safe food and water practices.

Short Descr GIARDIA AG IA
Medium Descr IAAD IA GIARDIA
Long Descr Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; giardia
Status Code Statutory Exclusion (from MPFS, may be paid under other methodologies)
Global Days XXX - Global Concept Does Not Apply
PC/TC Indicator (26, TC) 9 - Not Applicable
Multiple Procedures (51) 9 - Concept does not apply.
Bilateral Surgery (50) 9 - Concept does not apply.
Physician Supervisions 09 - Concept does not apply.
Assistant Surgeon (80, 82) 9 - Concept does not apply.
Co-Surgeons (62) 9 - Concept does not apply.
Team Surgery (66) 9 - Concept does not apply.
Diagnostic Imaging Family 99 - Concept Does Not Apply
CLIA Waived (QW) No
APC Status Indicator Conditionally packaged laboratory tests
Type of Service (TOS) 5 - Diagnostic Laboratory
Berenson-Eggers TOS (BETOS) T1H - Lab tests - other (non-Medicare fee schedule)
MUE 2
CCS Clinical Classification 206 - Microscopic examination (bacterial smear, culture, toxicology)
90 Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number.
59 Distinct procedural service: under certain circumstances, it may be necessary to indicate that a procedure or service was distinct or independent from other non-e/m services performed on the same day. modifier 59 is used to identify procedures/services, other than e/m services, that are not normally reported together, but are appropriate under the circumstances. documentation must support a different session, different procedure or surgery, different site or organ system, separate incision/excision, separate lesion, or separate injury (or area of injury in extensive injuries) not ordinarily encountered or performed on the same day by the same individual. however, when another already established modifier is appropriate it should be used rather than modifier 59. only if no more descriptive modifier is available, and the use of modifier 59 best explains the circumstances, should modifier 59 be used. note: modifier 59 should not be appended to an e/m service. to report a separate and distinct e/m service with a non-e/m service performed on the same date, see modifier 25.
Q4 Service for ordering/referring physician qualifies as a service exemption
GW Service not related to the hospice patient's terminal condition
XS Separate structure, a service that is distinct because it was performed on a separate organ/structure
91 Repeat clinical diagnostic laboratory test: in the course of treatment of the patient, it may be necessary to repeat the same laboratory test on the same day to obtain subsequent (multiple) test results. under these circumstances, the laboratory test performed can be identified by its usual procedure number and the addition of modifier 91. note: this modifier may not be used when tests are rerun to confirm initial results; due to testing problems with specimens or equipment; or for any other reason when a normal, one-time, reportable result is all that is required. this modifier may not be used when other code(s) describe a series of test results (eg, glucose tolerance tests, evocative/suppression testing). this modifier may only be used for laboratory test(s) performed more than once on the same day on the same patient.
26 Professional component: certain procedures are a combination of a physician or other qualified health care professional component and a technical component. when the physician or other qualified health care professional component is reported separately, the service may be identified by adding modifier 26 to the usual procedure number.
GA Waiver of liability statement issued as required by payer policy, individual case
GV Attending physician not employed or paid under arrangement by the patient's hospice provider
GY Item or service statutorily excluded, does not meet the definition of any medicare benefit or, for non-medicare insurers, is not a contract benefit
XE Separate encounter, a service that is distinct because it occurred during a separate encounter
XU Unusual non-overlapping service, the use of a service that is distinct because it does not overlap usual components of the main service
Date
Action
Notes
2022-01-01 Changed First appearance of change in codebook.
2022-01-01 Note Grammatical correction.
2021-01-01 Changed First appearance of change in CPT® Code Set.
2020-10-06 Changed Code changed.
2016-01-01 Changed Description Changed
2011-01-01 Changed Short description changed.
2007-01-01 Changed Code description changed.
2004-01-01 Added First appearance in code book in 2004.
Code
Description
Code
Description
Code
Description
CasePilot

Get instant expert-level medical coding assistance.

Ask about:
CPT Codes Guidelines Modifiers Crosswalks NCCI Edits Compliance Medicare Coverage
Example: "What is CPT code 99213?" or "Guidelines for E/M services"